Table 5 Clinical features of patients in different AML groups before chemotherapy

Sex

male

38

19

13

female

34

18

17

Age(year)

46(18–79)

48(18–69)

47(19–77)

WBC(×10⁹/L)

23.5(0.25-143)

11.83(2.96-101.69)

23.58(0.94-123.6)

Hb(g/L)

73(28–128)

111.5(69–135)

69(55–152)

PLT(×10⁹/L)

26(12–287)

74(48–174)

31(9–172)

Subtype

M0

0

M0

0

M0

0

M1

6

M1

2

M1

3

M2

8

M2

5

M2

2

M3

6

M3

5

M3

0

M4

24

M4

11

M4

13

M5

28

M5

14

M5

12

M6

0

M6

0

M6

0

M7

0

M7

0

M7

0

Chromosome Abnormality

t(15;17)

6

t(15;17)

5

t(8;21)

1

t(8;21)

4

t(8;21);

2

t(3;12)

2

t(3;12)

2

11q23

2

11q23

4

11q23

6

+8

3

+8

4

−7

2

−7

2

Molecular Genetics Abnormality

PML-RARa

6

PML-RARa

5

AML-ETO

1

AML-ETO

4

AML-ETO

2

MLL

3

MLL

6

FLT3-ITD

5

FLT3-ITD

6

C-kit Mut

2

C-kit

3

NPM1 Mut

3

NPM1 Mut

3

Sternal tenderness

57/72

25/37

26/30

Lymphadenectasis

39/72

14/37

21/30

Splenohepatomegalia

36/72

16/37

14/30

Curative effect

32/72

37/37

17/30